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Abstract
Purpose of Review We review recent studies of patients with septated malignant pleural effusions, to understand what the clinical
implications for patients are and what evidence-based methods should be used to manage these effusions.
Recent Findings Fibrinolytics improve effusion size assessed radiologically in patients with a chest drain inserted for septated
malignant pleural effusions but this does not translate into an improvement in breathlessness relief or pleurodesis success.
Fibrinolytics have also been used in patients with septated effusions associated with indwelling pleural catheters, but dyspnoea
relief has not been assessed in this population. Patients with septated effusions or extensive adhesions appear to have a worse
prognosis.
Summary Patients with septated malignant pleural effusions have a poor prognosis and do not gain clinical benefit from
fibrinolytics via chest drain. The role of fibrinolytics for septated effusions associated with indwelling pleural catheters requires
further study.
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Introduction
Malignant pleural effusions (MPEs), defined as the presence
of fluid in the pleural space secondary to cancer, are common
and cause disabling dyspnoea. Cost of hospitalisations related
to MPE was estimated to be over $5 billion in 2012 in the
USA alone [1]. MPEs are caused by mesothelioma or meta-
static cancer to the pleura. Patients have a median survival of
several months [2]. Treatment aims to provide prolonged dys-
pnoea relief while minimising the number of pleural drainage
procedures. This is achieved by either chest drainage and in-
jection of an irritant, such as talc, or via an indwelling pleural
catheter (IPC), a tunnelled semi-permanent catheter that is
drained at home [3]. However, septations can develop within
the fluid. These are formed from fibrin and divide the fluid
into separate pockets. This leads to failure of complete
drainage, leaving the patient with intractable dyspnoea.
Another complication associated with MPEs is the develop-
ment of trapped lung, in which chronically collapsed lung fails
to reexpand following pleural fluid drainage, due to the devel-
opment of a thickened visceral pleura. This article reviews our
current understanding of how we should manage patients with
septated MPEs.
Aetiology
Development of pleural fluid septations is thought to be due to
activation of the coagulation cascade, resulting in deposition
of fibrin to form fibrin sheets. Chung et al. demonstrated that
repeated thoracenteses over 3 days led to an increase in the
levels of pleural fluid inflammatory markers (tumour necrosis
factor (TNF)-alpha, interleukin (IL)-8 and neutrophil count)
and activation of the coagulation cascade in the pleural space,
as measured by plasminogen activator inhibitor type 1 (PAI-1)
levels [4]. By day 6, 11/26 (42%) had developed septations
visible on ultrasound. The patients who developed septations
had greater increase in PAI-1 levels, supporting the hypothesis
that activation of the coagulation cascade in pleural fluid leads
to fibrin deposition and septation formation and suggests that
one stimulus for this is invasive pleural procedures.
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We compared patient characteristics of patients whose
pleural effusion did not drain following chest drain insertion
(presumed to be due to the presence of septations, recruited to
a randomised trial of intrapleural fibrinolytics versus placebo
for MPEs [5••]) and unselected patients with MPEs (recruited
to a randomised trial of chest drain and pleurodesis versus IPC
[2]), in order to identify patient characteristics associated with
non-draining MPE [6•]. Patients with non-draining MPEs had
a significantly higher pleural fluid lactate dehydrogenase
(LDH) level (mean 1900 (SD 3100) versus 660 (SD 840),
p < 0.001) and systemic C-reactive protein (CRP) levels
(mean 117 (SD 80) versus 62 (SD 55), p < 0.001). These pa-
tients were on average 4 years older, but there was no differ-
ence in sex, performance status, type of malignancy or pleural
fluid pH, glucose or total protein levels. This data suggests
that patients with septated effusions have higher levels of sys-
temic inflammation and pleural fluid metabolic activity. These
variables may lead to activation of the coagulation cascade in
the pleural space with fibrin deposition.
As well as thin fibrin septations, dense vascularised adhe-
sions can be found in the pleural space. The relationship be-
tween adhesions and septations is not clear, although it seems
a reasonable hypothesis that, with time, fibrinous septations
become infiltrated with fibroblasts, and there is deposition of
collagen, leading to development of adhesions. However,
these terms are not clearly defined and use varies between
authors.
Incidence
The proportion of MPEs with septations is not known. Bielsa
et al. found significant adhesions (defined as obstruction of
one third or more of the vision on thoracoscopy) in 40% of
patients [7]. Of the 692 patients with chest drain inserted for
MPE screened for recruitment into a randomised controlled
trial of intrapleural fibrinolytic versus placebo (TIME3), 115
did not drain fully, suggesting that about 16% of patients with
MPE have sufficient septations to affect drainage [5••].
However, other factors may affect drainage completeness,
such as trapped lung and negative pleural pressure. It is likely
that mildly septated effusions still drain well because the
septations do not form complete barriers to flow of fluid.
However, heavy septations or dense adhesions may lead to
failure to drain.
Investigations
Septations are clearly visible on thoracic ultrasound. The in-
crease in availability of ultrasoundmachines and of physician-
performed thoracic ultrasound has led to an increase in the rate
of recognition of pleural septations. Ultrasound prior to
medical thoracoscopy has been shown to reliably identify ad-
hesions and help improve pleural space access [8]. Our clini-
cal practice has previously been to subjectively categorise
effusions as unseptated, mildly septated, moderately septated
and heavily septated. However, we recognised that this sub-
jective assessment may not be reproducible between operators
and centres. For this reason, we developed and validated an
objective thoracic ultrasound septation score. This score cate-
gorises effusions based on the extent of septations
(unseptated, heterogeneously septated and homogenously
septated) and the number of septations at the most septated
point (0, 1–2, 3–4, > = 5). This score shows good interrater
reliability and corresponds to our previous subjective
categorisation (personal data). In patients with chest drain
inserted for a pleural effusion, we found a negative correlation
between number of septations and dyspnoea relief [9].
Computer tomography is routinely performed in patients
with suspected MPE. Septations are not visible on CT, al-
though there may be signs to suggest that there are septations
such as air pockets within the fluid or there may be visible
adhesions between the visceral and parietal pleura.
Septations may also be seen at thoracoscopy and this al-
lows the thoracoscopist to distinguish between thin fibrinous
septations, which can be easily divided with the thoracoscope,
and dense adhesions in which blood vessels are visible.
Treatment
In patients withMPEwho have developed a septated effusion,
fibrinolytics have been used to dissolve the septations, with
the ultimate aims of relieving breathlessness and improving
pleurodesis success. Thoracic ultrasound performed before
and after administration of pleural fibrinolytic demonstrates
the dissolution of septations [10]. To date, there have been
three randomised controlled trials of pleural fibrinolytics in
patients with MPEs which have been treated with chest drain
insertion. TIME3 randomised 71 patients with non-draining
MPEs to either pleural urokinase (100,000 IU, three doses at
12-h interval) or placebo [5••]. Okur et al. randomised 47
unselected patients with MPE to either pleural streptokinase
(250,000 IU, three doses at 12-interval) or no treatment [11].
Saydam el al. randomised 40 patients with multiloculated
MPE to either pleural streptokinase (250,000 IU, four doses
at 12-h interval) or saline [12].
In TIME3, we found patients had significant residual dys-
pnoea following urokinase/placebo administration, with no
significant difference between the groups (mean VAS dys-
pnoea over 28 days 39 mm urokinase group versus 35 mm
placebo group, p = 0.36). There was no difference in the pro-
portion of patients who experienced a clinically significant
decrease in dyspnoea (> = 19 mm, 13/36 urokinase group,
15/35 placebo group). Dyspnoea was not directly assessed in
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the trials by Okur and Saydam. Saydam et al. used oxygen use
as a substitute for dyspnoea and found that 18 patients (90%)
no longer required oxygen in the fibrinolytic group and 11
patients (55%) in the control group (p = 0.03). However, use
of oxygen was determined by the treating physicians and the
blinding is not clear, so this outcome may have been subject to
bias or a placebo effect on patients.
All three studies showed an improvement in radiological
appearance following pleural fibrinolytics, based on chest X-
ray or computer tomography appearance. Although there was
a trend to increased pleural fluid drainage in TIME3 and the
study by Okur, this only reached statistical significance in the
study by Saydam. These data demonstrate that pleural fibri-
nolytics decrease size of effusion, probably by increased pleu-
ral fluid drainage, but this does not translate into an improve-
ment in dyspnoea. The implication for future trials is that
direct measurement of dyspnoea should be the primary
outcome.
Concerns have been raised that the use of pleural fibrino-
lytics in patients with MPE could reduce pleurodesis efficacy,
but there were no significant differences in pleurodesis failure
rates between patients who received pleural fibrinolytics and
those who did not in the three trials discussed [5••, 11, 12]. It is
likely that the short half time of pleural fibrinolytics in vivo
means there is no impact on subsequent instillation of
pleurodesis agents.
Septated effusions also develop in patients with IPCs,
possibly due to the inflammatory effect of repeated drain-
age. This is estimated to occur in 6–14% of patients [2, 13].
Two retrospective case series of the use of pleural fibrino-
lytics in patients with IPCs who have developed symptom-
atic loculations have been published, one of 97 patients in
a single centre where tissue plasminogen activator (tPA)
was used [14] and the other from 4 IPC centres in 66
patients [15•], where a variety of fibrinolytics were used
(tPA, 52 patients; urokinase, 12 patients; streptokinase, 2
patients). In the second series, the majority of fibrinolytic
instillations were performed as outpatients (61%), and
most patients (69.7%) only had a single dose of fibrinolyt-
ic. Pleural fluid drainage increased in 93% of patients and
dyspnoea improved in 83% of patients.
The key concern over administration of pleural fibrino-
lytics in patients with pleural effusions is the risk of pleural
haemorrhage. This is a particular concern in MPEs, where
pleural tumour stimulates the development of new blood
vessels, which can be friable and prone to bleeding. No
cases of pleural or systemic haemorrhage were reported
in the 80 patients receiving pleural fibrinolytics in the three
trials discussed above [11, 12]. Of the four published case
series of pleural fibrinolytics given via chest drain in MPE
with a total of 101 patients, there were no cases of pleural
haemorrhage reported [16–19]. In the two case series of
patients receiving pleural fibrinolytics, a total of four cases
of nonfatal pleural bleed out of 163 patients (2%) were
reported [14, 15•]. This suggests that pleural fibrinolytics
are safe in patients with MPEs, with a possible excess risk
in patients with IPCs, but numbers are small and may be
subject to reporting bias.
These data suggest that although pleural fibrinolytics given
via chest drain to patients with septatedMPEs are safe and can
improve drainage volumes and effusion size, this does not
translate to an improvement in dyspnoea. Given the poor
prognosis and intractable dyspnoea in this patient group, we
should question whether these patients should have a chest
drain at all. Alternative palliative measures for controlling
dyspnoea, such as intermittent therapeutic aspiration or opi-
ates, may bemore appropriate. The role of pleural fibrinolytics
in patients with IPCs requires further study.
Survival
MPEs are associatedwith a median survival of about 6 months
[2]. However, there is some evidence that patients with pleural
fluid septations or adhesions have a worse prognosis. We
found patients with a septated, non-draining MPE to have a
poor survival with a median time to death of 58 days (inter-
quartile range 27–123) compared to 187 days (interquartile
range 48–358) in unselected patients with MPE [2, 5•].
Bielsa et al. also found that patients with adhesions observed
at thoracoscopy had a shorter survival, with patients with most
extensive adhesions having amedian time to death of 5months
compared to 9 months in patients with minimal or no adhe-
sions [7]. This poor survival should be taken into account
when managing these patients.
Parallels with Pleural Infection
Pleural infection, with both typical bacteria and tuberculosis,
is also associated with septation development. This makes the
effusion more difficult to drain. As with MPEs, randomised
trials have demonstrated that fibrinolytics alone improve pleu-
ral fluid drainage and radiological appearance but this does
not translate into improved clinical outcomes (mortality and
need for surgery) [20]. Subsequent work has suggested that
the use of DNAse in conjunction with fibrinolytics may re-
duce need for surgery and length of hospital stay [21]. This
work has been applied to patients with MPEs, with a pub-
lished case series of use of DNAse/alteplase in patients with
MPEs [19]. However, it should be noted that this is a different
patient population with a different pathology with a different




There is a role for a longitudinal cohort study to understand
why septated effusions develop, their incidence and clinical
significance. This would help us understand whether fibrous
septations progress into vascularised adhesions or whether
these are separate processes. This will help improve treatment
algorithms, for example, demonstration that repeated pleural
procedures increase risk of septation development will strength
the argument for going straight to a definitive treatment.
Clinical trials of DNAse/fibrinolytics in septated effusions and
fibrinolytics in non-draining IPCs will guide future manage-
ment but dyspnoea relief must be the primary outcome, rather
than radiological appearance or volume drained. Identification
of trapped lung should also be an outcome measure. However,
given that 692 patients were screen to randomise 71 in our trial
of non-draining MPEs, it is unlikely that further adequately-
powered trials will be performed in this population.
Summary
Septated MPEs are associated with poor prognosis. Although
fibrinolytics appear to improve effusion size in patients with
chest drains, this does not translate into relief of breathless-
ness, and alternative palliative measures should be used in
these patients. The role of fibrinolytics in patients with IPCs
needs further study.
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